Artículos de revistas sobre el tema "Drug repurposing against Aurora-kinases"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Drug repurposing against Aurora-kinases".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Islam, Saiful, Theodosia Teo, Malika Kumarasiri, Martin Slater, Jennifer H. Martin, Shudong Wang y Richard Head. "Combined In Silico and In Vitro Evidence Supporting an Aurora A Kinase Inhibitory Role of the Anti-Viral Drug Rilpivirine and an Anti-Proliferative Influence on Cancer Cells". Pharmaceuticals 15, n.º 10 (25 de septiembre de 2022): 1186. http://dx.doi.org/10.3390/ph15101186.
Texto completoPereira Moreira, Bernardo, Michael H. W. Weber, Simone Haeberlein, Annika S. Mokosch, Bernhard Spengler, Christoph G. Grevelding y Franco H. Falcone. "Drug Repurposing and De Novo Drug Discovery of Protein Kinase Inhibitors as New Drugs against Schistosomiasis". Molecules 27, n.º 4 (19 de febrero de 2022): 1414. http://dx.doi.org/10.3390/molecules27041414.
Texto completoPatel, Gautam, Norma E. Roncal, Patricia J. Lee, Susan E. Leed, Jessey Erath, Ana Rodriguez, Richard J. Sciotti y Michael P. Pollastri. "Repurposing human Aurora kinase inhibitors as leads for anti-protozoan drug discovery". Med. Chem. Commun. 5, n.º 5 (2014): 655–58. http://dx.doi.org/10.1039/c4md00045e.
Texto completoRegan-Fendt, Kelly, Ding Li, Ryan Reyes, Lianbo Yu, Nissar A. Wani, Peng Hu, Samson T. Jacob, Kalpana Ghoshal, Philip R. O. Payne y Tasneem Motiwala. "Transcriptomics-Based Drug Repurposing Approach Identifies Novel Drugs against Sorafenib-Resistant Hepatocellular Carcinoma". Cancers 12, n.º 10 (23 de septiembre de 2020): 2730. http://dx.doi.org/10.3390/cancers12102730.
Texto completoFerrarelli, Leslie K. "Repurposing an HIV drug for melanoma". Science Signaling 9, n.º 423 (12 de abril de 2016): ec85-ec85. http://dx.doi.org/10.1126/scisignal.aaf8440.
Texto completoYu, Ga-Ram, Seung-Jun Lee, Dong-Woo Lim, Hyuck Kim, Jai-Eun Kim y Won-Hwan Park. "Drug Repurposing in Alternative Medicine: Sochehwan, a Polyherbal Traditional Korean Digestant, Protects against Alcoholic Steatohepatitis by Regulating Cytochrome P450 2E1 Expression". Processes 9, n.º 10 (30 de septiembre de 2021): 1760. http://dx.doi.org/10.3390/pr9101760.
Texto completoThirunavukkarasu, Muthu Kumar, Utid Suriya, Thanyada Rungrotmongkol y Ramanathan Karuppasamy. "In Silico Screening of Available Drugs Targeting Non-Small Cell Lung Cancer Targets: A Drug Repurposing Approach". Pharmaceutics 14, n.º 1 (28 de diciembre de 2021): 59. http://dx.doi.org/10.3390/pharmaceutics14010059.
Texto completoHan, Hyun-Ju y Chang-Gu Hyun. "Acenocoumarol Exerts Anti-Inflammatory Activity via the Suppression of NF-κB and MAPK Pathways in RAW 264.7 Cells". Molecules 28, n.º 5 (22 de febrero de 2023): 2075. http://dx.doi.org/10.3390/molecules28052075.
Texto completoR. Sahrawat, Tammanna y Prabhjeet Kaur Kaur. "Polypharmacological study of Ceritinib using a structure based in silico approach". Bionatura 4, n.º 2 (15 de mayo de 2019): 836–40. http://dx.doi.org/10.21931/rb/2019.04.02.3.
Texto completoBrunotte, Linda, Shuyu Zheng, Angeles Mecate-Zambrano, Jing Tang, Stephan Ludwig, Ursula Rescher y Sebastian Schloer. "Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In Vitro". Pharmaceutics 13, n.º 9 (3 de septiembre de 2021): 1400. http://dx.doi.org/10.3390/pharmaceutics13091400.
Texto completoElkamhawy, Ahmed, Usama M. Ammar, Sora Paik, Magda H. Abdellattif, Mohamed H. Elsherbeny, Kyeong Lee y Eun Joo Roh. "Scaffold Repurposing of In-House Small Molecule Candidates Leads to Discovery of First-in-Class CDK-1/HER-2 Dual Inhibitors: In Vitro and In Silico Screening". Molecules 26, n.º 17 (1 de septiembre de 2021): 5324. http://dx.doi.org/10.3390/molecules26175324.
Texto completoMeijer, Laurent, Deborah J. Nelson, Vladimir Riazanski, Aida G. Gabdoulkhakova, Geneviève Hery-Arnaud, Rozenn Le Berre, Nadège Loaëc et al. "Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis". Journal of Innate Immunity 8, n.º 4 (2016): 330–49. http://dx.doi.org/10.1159/000444256.
Texto completoMaxson, Julia Elizabeth, Abel L. Melissa, Jinhua Wang, Xianming Deng, Samuel B. Luty, Huahang Sun, Julie Gorenstein et al. "Development and Repurposing of Small-Molecule Kinase Inhibitors to Target Novel Leukemogenic TNK2 Mutations". Blood 124, n.º 21 (6 de diciembre de 2014): 435. http://dx.doi.org/10.1182/blood.v124.21.435.435.
Texto completoChen, Ya-Ping, Hui-Ju Lin, Kung-Chao Chang, Jiann-Shiuh Chen, Ming-Ying Tsai, Liang-Yi Hung y Tsai-Yun Chen. "Targeting Aurora Kinases in Acute Lymphoblastic Leukemia". Blood 120, n.º 21 (16 de noviembre de 2012): 4907. http://dx.doi.org/10.1182/blood.v120.21.4907.4907.
Texto completoManey, N., H. De Paula-Lemos, B. Barron-Millar, A. Mellor, J. D. Isaacs, A. Anderson y A. Pratt. "SAT0013 PIM-1 KINASE IS A MEASURABLE MEDIATOR OF CD4+ T CELL DYSREGULATION AND THERAPEUTIC TARGET IN EARLY RHEUMATOID ARTHRITIS". Annals of the Rheumatic Diseases 79, Suppl 1 (junio de 2020): 936.1–937. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2818.
Texto completoMoore, Andrew S., Amir Faisal, Vassilios Bavetsias, Chongbo Sun, Butrus Atrash, Melanie Valenti, Alexis de Haven Brandon et al. "Dual Inhibition of Aurora and FLT3 Kinases by CCT137690: A Novel Treatment Strategy Against FLT3-ITD Positive AML In Vitro and In Vivo". Blood 116, n.º 21 (19 de noviembre de 2010): 3289. http://dx.doi.org/10.1182/blood.v116.21.3289.3289.
Texto completoReiman, Tony, Robert P. Evans, Claudia Naber, Tara Steffler, Jonathan J. Keats, Troy Perry, Christopher A. Maxwell, Heidi Chau, Andrew R. Belch y Linda M. Pilarski. "Aurora Kinases as Therapeutic Targets in Multiple Myeloma." Blood 108, n.º 11 (16 de noviembre de 2006): 847. http://dx.doi.org/10.1182/blood.v108.11.847.847.
Texto completoBesse, Lenka, Andrej Besse, Marianne Kraus, Matej Jasik, Ondrej Slaby y Christoph Driessen. "Abstract 2851: ALK-inhibitors as a novel potential therapy for proteasome inhibitor-resistant multiple myeloma". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 2851. http://dx.doi.org/10.1158/1538-7445.am2023-2851.
Texto completoPollard, John R., Peter A. Charlton, Graham M. T. Cheetham, Susanna C. Falcon, Julian M. C. Golec, Matthew R. Griffiths y Peter Weber. "Structural Basis and Cellular Consequences of Potent Inhibition of the Aurora Kinases, Wild Type Abl Kinase and a T315I Multi-Drug Resistant Mutant Form of Abl Kinase by MK-0457 (VX-680)." Blood 108, n.º 11 (16 de noviembre de 2006): 1368. http://dx.doi.org/10.1182/blood.v108.11.1368.1368.
Texto completoKaratas, Mehmet, Apirat Chaikuad, Bianca Berger, Michael H. G. Kubbutat, Frank Totzke, Stefan Knapp y Conrad Kunick. "7-(2-Anilinopyrimidin-4-yl)-1-benzazepin-2-ones Designed by a “Cut and Glue” Strategy Are Dual Aurora A/VEGF-R Kinase Inhibitors". Molecules 26, n.º 6 (14 de marzo de 2021): 1611. http://dx.doi.org/10.3390/molecules26061611.
Texto completoOkabe, Seiichi, Tetsuzo Tauchi, Seiichiro Katagiri, Yuko Tanaka y Kazuma Ohyashiki. "Activity of the Aurora Kinase Inhibitor, MLN8237 (alisertib) Alone or in Combination with Ponatinib Against Imatinib-Resistant BCR-ABL-Positive Cells". Blood 120, n.º 21 (16 de noviembre de 2012): 1333. http://dx.doi.org/10.1182/blood.v120.21.1333.1333.
Texto completoCheung, Kam, Gloria Juan, William Wayne, Kelly Hanestad, Kathleen Keegan, Justin Huard, Patricia McElroy et al. "AMG 900, a Potent and Highly Selective Aurora Kinase Inhibitor Shows Promising Preclinical Activity Against Acute Myeloid Leukemia Cell Lines In Vitro and In Vivo". Blood 122, n.º 21 (15 de noviembre de 2013): 3823. http://dx.doi.org/10.1182/blood.v122.21.3823.3823.
Texto completoIslam, Saiful, Muhammed H. Rahaman, Mingfeng Yu, Benjamin Noll, Jennifer H. Martin, Shudong Wang y Richard Head. "Anti-Leukaemic Activity of Rilpivirine Is Mediated by Aurora A Kinase Inhibition". Cancers 15, n.º 4 (7 de febrero de 2023): 1044. http://dx.doi.org/10.3390/cancers15041044.
Texto completoLunghi, Paolo, Laura Mazzera, Guerino Lombardi, Micaela Ricca, Manuela Abeltino, Davide Arienti, Anna Maria Cantoni, Attilio Corradi y Antonio Bonati. "Pan-Aurora Kinases and TRAIL Combination Therapy Has Potent Antitumor Activity In Vivo Against Drug-Resistant Human Multiple Myeloma Xenograft Model". Blood 118, n.º 21 (18 de noviembre de 2011): 1846. http://dx.doi.org/10.1182/blood.v118.21.1846.1846.
Texto completoAbdusalam, Ashraf Ahmed Ali. "In-silico identification of novel inhibitors for human Aurora kinase B form the ZINC database using molecular docking-based virtual screening". Research Results in Pharmacology 8, n.º 4 (15 de diciembre de 2022): 89–99. http://dx.doi.org/10.3897/rrpharmacology.8.82977.
Texto completoBhongade, Bhoomendra A., Nikhil D. Amnerkar y Andanappa K. Gadad. "3D-QSAR Studies on 4,5-Dihydro-1H-pyrazolo [4,3-h] Quinazolines as Plk-1, CDK2/A and Aur-A Serine/Threonine Kinase Inhibitors". Letters in Drug Design & Discovery 17, n.º 4 (25 de abril de 2020): 388–95. http://dx.doi.org/10.2174/1570180816666190611161332.
Texto completoGou, Xuxu, Beom-Jun Kim, Meenakshi Anurag, Jonathan T. Lei, Meggie N. Young, Matthew V. Holt, Diana Fandino et al. "Abstract 5011: Targeting kinome reprogramming in ESR1 fusion-driven breast cancer". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 5011. http://dx.doi.org/10.1158/1538-7445.am2023-5011.
Texto completoBehera, Ranjan, Sarah M. Thomas y Kojo Mensa-Wilmot. "New Chemical Scaffolds for Human African Trypanosomiasis Lead Discovery from a Screen of Tyrosine Kinase Inhibitor Drugs". Antimicrobial Agents and Chemotherapy 58, n.º 4 (27 de enero de 2014): 2202–10. http://dx.doi.org/10.1128/aac.01691-13.
Texto completoHargrave, Darren R., Andrew DJ Pearson, Lucas Moreno, Bruce Morland, Martin Elliott, Guy Makin, Quentin Campbell-Hewson et al. "A phase I trial of AT9283 (a selective inhibitor of Aurora kinases) given for 72 hours every 21 days via intravenous infusion in children and adolescents with relapsed and refractory solid tumours." Journal of Clinical Oncology 30, n.º 15_suppl (20 de mayo de 2012): 9542. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.9542.
Texto completoPodesta, Jennifer E., Melanie J. Griffin, Richard Sugar, Matthew S. Squires, Alan Boddy, Spiros Linardopoulos, Andrew DJ Pearson y Andrew S. Moore. "Adaptation and Validation of the Plasma Inhibitory Activity (PIA) Assay to Detect Inhibition of Aurora, ABL and FLT3 Kinases by AT9283 In Children and Adolescents with Leukaemia". Blood 116, n.º 21 (19 de noviembre de 2010): 1818. http://dx.doi.org/10.1182/blood.v116.21.1818.1818.
Texto completoLee, Kyeong, Hossam Nada, Hyun Jung Byun, Chang Hoon Lee y Ahmed Elkamhawy. "Hit Identification of a Novel Quinazoline Sulfonamide as a Promising EphB3 Inhibitor: Design, Virtual Combinatorial Library, Synthesis, Biological Evaluation, and Docking Simulation Studies". Pharmaceuticals 14, n.º 12 (30 de noviembre de 2021): 1247. http://dx.doi.org/10.3390/ph14121247.
Texto completoMoore, Andrew S., Amir Faisal, Vassilios Bavetsias, David Gonzalez de Castro, Chongbo Sun, Butrus Atrash, Melanie Valenti et al. "Resistance to Selective FLT3 Inhibitors, Driven by FLT3 Ligand and FLT3 Point Mutations, Can Be Overcome with the Dual FLT3-Aurora Kinase Inhibitor CCT241736",. Blood 118, n.º 21 (18 de noviembre de 2011): 3492. http://dx.doi.org/10.1182/blood.v118.21.3492.3492.
Texto completoPanicker, Resmi C., Anthony G. Coyne y Rajavel Srinivasan. "Allosteric Targeting of Aurora A Kinase Using Small Molecules: A Step Forward Towards Next Generation Medicines?" Current Medicinal Chemistry 26, n.º 13 (8 de julio de 2019): 2234–42. http://dx.doi.org/10.2174/0929867324666170727120315.
Texto completoHembrough, Todd A., Xiaoru Chen, Patricia A. Burke, Glenn M. Swartz, Kathleen Bengali, Richard Brokx, Theresa M. LaVallee y Mark R. Bray. "Inhibition of Multiple Myeloma Tumor Growth and FGFR3 by the Aurora-Angiogenesis Inhibitor ENMD-981693." Blood 110, n.º 11 (16 de noviembre de 2007): 1209. http://dx.doi.org/10.1182/blood.v110.11.1209.1209.
Texto completoLotfi, Shamim, Aarthi Jayanthan, Victor A. Lewis, Greg Guilcher, Matthew S. Squires, Todd Cooper y Aru Narendran. "AT9283, A Novel Aurora Kinase/Jak2 Inhibitor Demonstrates Activity against Refractory Infant Leukemia Cells: Studies On Growth Inhibition, Biological Correlates, Drug Synergy and Effects On Leukemia Stem-Like Cells." Blood 114, n.º 22 (20 de noviembre de 2009): 3078. http://dx.doi.org/10.1182/blood.v114.22.3078.3078.
Texto completoSanto, Loredana, Teru Hideshima, Diana Cirstea, Madhavi L. Bandi, Erik A. Nelson, Hiroshi Ikeda, Sonia Vallet et al. "AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity". Blood 116, n.º 21 (19 de noviembre de 2010): 2994. http://dx.doi.org/10.1182/blood.v116.21.2994.2994.
Texto completoChang, Bill H., Jessica Leonard, Joelle Wolf, Michelle Degnin, Kyle Lenz, Beth Wilmot, Charles G. Mullighan et al. "Significant In Vivo Sensitivity to Aurora Kinase Inhibition in TCF3-Hlf rearranged Acute Lymphoblastic Leukemia". Blood 132, Supplement 1 (29 de noviembre de 2018): 4026. http://dx.doi.org/10.1182/blood-2018-99-115706.
Texto completoGriffin, Patrick, Steffan T. Nawrocki, Takashi Satou, Claudia M. Espitia, Kevin R. Kelly, Maki Hasegawa, Swaminathan Padmanabhan, Angela Romanelli, Ron de Jong y Jennifer S. Carew. "The Investigational Multi-Targeted Kinase Inhibitor TAK-901 Antagonizes Acute Myeloid Leukemia Pathogenesis: Results of Preclinical Studies". Blood 118, n.º 21 (18 de noviembre de 2011): 581. http://dx.doi.org/10.1182/blood.v118.21.581.581.
Texto completoLi, Lingxiao, Praechompoo Pongtornpipat, Soham D. Puvvada y Jonathan H. Schatz. "Targeting MYC Expression With CDK Inhibitors Shows Potency In Preclinical Models Of High-Risk Diffuse Large B-Cell Lymphom". Blood 122, n.º 21 (15 de noviembre de 2013): 1831. http://dx.doi.org/10.1182/blood.v122.21.1831.1831.
Texto completoBrummendorf, Tim H., Artur Gontarewicz, Gunhild Keller, Jürgen Moll, Melanie Braig, Imke Rohe, Edgar Jost et al. "Resistance to Danusertib (formerly PHA-739358) in BCR-ABL-Positive Cells Is Mediated by Upregulation of the Drug Transporter Abcg2 and Can Be Suppressed in Vitro by Combination Treatment with Imatinib." Blood 114, n.º 22 (20 de noviembre de 2009): 1724. http://dx.doi.org/10.1182/blood.v114.22.1724.1724.
Texto completoGiles, Francis, Jorge Cortes, Donald A. Bergstrom, Alan Xiao, Penny Bristow, Dan Jones, Srdan Verstovsek, Deborah Thomas, Hagop Kantarjian y Steven J. Freedman. "MK-0457, a Novel Aurora Kinase and BCR-ABL Inhibitor, Is Active Against BCR-ABL T315I Mutant Chronic Myelogenous Leukemia (CML)." Blood 108, n.º 11 (16 de noviembre de 2006): 163. http://dx.doi.org/10.1182/blood.v108.11.163.163.
Texto completoGauler, Thomas Christoph, Benjamin Besse, Silvia Novello, Egbert F. Smit, Elizabeth R. Plummer, Jean-Pierre Delord, Maurizio Nicodemo et al. "Phase II study of danusertib (D) in advanced/metastatic non-small cell lung cancers (NSCLC)." Journal of Clinical Oncology 31, n.º 15_suppl (20 de mayo de 2013): e19138-e19138. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e19138.
Texto completoShah, Pooja A., Tuhina Mazumdar, Reid T. Powell, Li Shen, Jing Wang, Clifford C. Stephen, Mitchell J. Frederick y Faye M. Johnson. "Abstract 2847: Concurrent inactivation of PI3K and PLK1 is synergistic and overcomes acquired resistance to PI3K inhibitors in NOTCH1MUT HNSCC". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 2847. http://dx.doi.org/10.1158/1538-7445.am2023-2847.
Texto completoTauchi, Tetsuzo, Daigo Akahane, Kousuke Nunoda, Seiichi Okabe, John Pollard y Kazuma Ohyashiki. "Combined Effects of a Pan-Aurora Kinase Inhibitor MK-0457 and Dasatinib Against T315I Mutant Form of BCR-ABL: In Vitro and In Vivo Studies." Blood 110, n.º 11 (16 de noviembre de 2007): 805. http://dx.doi.org/10.1182/blood.v110.11.805.805.
Texto completoLawasut, Panisinee, Hannah M. Jacobs, Jake E. Delmore, Joseph Negri, Douglas W. McMillin, Ellen L. Weisberg, James D. Griffin, Paul G. Richardson, Kenneth C. Anderson y Constantine S. Mitsiades. "In Vitro Anti-Myeloma Activity of the Multitargeted Kinase Inhibitor Midostaurin in the Context of Heterotypic Cocultures of Myeloma Cells with Nonmalignant Microenvironmental Accessory Cells". Blood 118, n.º 21 (18 de noviembre de 2011): 2923. http://dx.doi.org/10.1182/blood.v118.21.2923.2923.
Texto completoCortes, Jorge, Gail J. Roboz, Hagop Kantarjian, Eric Feldman, Judy Karp, Allyson Pollack, Katrina Sandy, Niranjan Rao, Shiro Akinaga y Mark Levis. "A Phase I Dose Escalation Study of KW-2449, an Oral Multi-Kinase Inhibitor Against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, Treatment Resistant/Intolerant CML, ALL and MDS." Blood 110, n.º 11 (16 de noviembre de 2007): 909. http://dx.doi.org/10.1182/blood.v110.11.909.909.
Texto completoBagashev, Asen, Joseph Patrick Loftus, Colin Wakefield, Gerald Wertheim, Christian Hurtz, Martin P. Carroll, Kimberly Stegmaier, Yana Pikman y Sarah K. Tasian. "Alisertib Synergistically Strengthens the Anti-Leukemia Activity of Venetoclax in TCF3-Hlf B-ALL". Blood 138, Supplement 1 (5 de noviembre de 2021): 705. http://dx.doi.org/10.1182/blood-2021-148671.
Texto completoDelmore, Jake, David N. Cervi, Douglas McMillin, Efstathios Kastritis, Jana Jakubikova, Melissa G. Ooi, Steffen Klippel et al. "The Transcriptional Signature of Kinases Inhibited by the Multi-Targeted Kinase Inhibitor AS703569 Is Associated with Clinical Outcome in Multiple Myeloma (MM): Anti-MM Activity of AS703569 in Preclinical Studies." Blood 114, n.º 22 (20 de noviembre de 2009): 730. http://dx.doi.org/10.1182/blood.v114.22.730.730.
Texto completoMastrogamvraki, Natalia y Apostolos Zaravinos. "Signatures of co-deregulated genes and their transcriptional regulators in colorectal cancer". npj Systems Biology and Applications 6, n.º 1 (31 de julio de 2020). http://dx.doi.org/10.1038/s41540-020-00144-8.
Texto completoPatnaik, Sunil Kumar, Akey Krishna Swaroop, Mudavath Ravi Naik, Jubie Selvaraj y Moola Joghee Nanjan Chandrasekar. "Repurposing of FDA Approved Drugs and Neuropep peptides as Anticancer Agents Against ErbB1 and ErbB2". Drug Research, 17 de abril de 2023. http://dx.doi.org/10.1055/a-2030-4078.
Texto completo